Status:
COMPLETED
Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical te...
Eligibility Criteria
Inclusion
- Any subject with Type 1 or Type 2 diabetes and accepting to use NovoPen® 4. The selection will be at the discretion of the individual physician.
- A study specific signed informed consent must be signed by each subject before any study-related activities or information is collected, if required by local regulations
Exclusion
- Subjects who are unlikely to comply with the protocol, e.g., unwillingness to cooperate, inability to return for the final visit
- Subjects with known or suspected allergy to any insulin or any of its excipients
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
526 Patients enrolled
Trial Details
Trial ID
NCT00806858
Start Date
November 1 2008
End Date
July 1 2009
Last Update
November 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100004